In a randomized clinical trial, researchers from Huntsman Cancer Institute at the University of Utah (the U) have found that short-course, higher dose vaginal brachytherapy for endometrial cancer had ...

How common is endometrial cancer? In the United States, cancer of the endometrium (the lining of the uterus) is the most common cancer of the female reproductive organs. The American Cancer Society ...

A woman who thought she was experiencing symptoms of the menopause actually went on to be diagnosed with womb cancer and now ...

Dawn Willis, 58, is now cancer-free and is speaking out in the hopes of raising awareness and hopefully “saving someone’s life.” ...

IMA-402 is under clinical development by Immatics and currently in Phase II for Uterine Cancer. According to GlobalData, Phase II drugs for Uterine Cancer have a 30% phase transition success rate ...

In a high-profile incident, Saif Ali Khan returned home smiling after being discharged from the hospital following an attack at his Bandra East apartment. The case has raised serious questions about ...

Compared with chemotherapy alone, the addition of radiation to chemotherapy did not improve overall or recurrence-free survival in patients with locally advanced endometrial cancer, a new phase 3 ...

Immunotherapy represents a groundbreaking therapeutic approach, based on the immune system’s intrinsic capacity to interfere with tumor progression, that opens the horizons in the treatment of ...

Cancer remains a leading cause of death globally, with breast cancer being the most fatal for women. A recent American Cancer Society report highlights increasing cancer rates among women ...

Black people are 2 times more likely to die from prostate, stomach, and uterine cancer than White people. The risk of developing cancer varies markedly by age and by sex. Middle-aged women now have a ...

By Roni Caryn Rabin More Americans are surviving cancer, but the disease is striking young and middle-aged adults and women more frequently, the American Cancer Society reported on Thursday.

Lenvima plus Keytruda did not significantly improve survival or progression-free survival compared to chemotherapy in advanced endometrial cancer. The study involved 842 patients, with no new safety ...